Literature DB >> 2678947

Perspectives on the role of MHC antigens in normal and malignant cell development.

B E Elliott1, D A Carlow, A M Rodricks, A Wade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2678947     DOI： 10.1016/s0065-230x(08)60282-1

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  29 in total

Review 1.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

2.  Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant.

Authors:  S P Cole; B M Campigotto; J G Johnson; B E Elliott
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 3.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

4.  Absence of HLA class I expression by Reed-Sternberg cells.

Authors:  S Poppema; L Visser
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

5.  Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.

Authors:  E Shiloni; S E Karp; M C Custer; J Shilyansky; N P Restifo; S A Rosenberg; J J Mulé
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

6.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

7.  Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

Authors:  N P Restifo; F Esquivel; A L Asher; H Stötter; R J Barth; J R Bennink; J J Mulé; J W Yewdell; S A Rosenberg
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

8.  Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

Authors:  B L Petersen; O Braendstrup
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

9.  Characterization of defectiveness in endogenous antigen presentation of novel murine cells established from methylcholanthrene-induced fibrosarcomas.

Authors:  K Kuroda; K Yamashina; N Kitatani; A Kagishima; T Hamaoka; Y Hosaka
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

10.  MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.

Authors:  T S Kim; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.